Clinical trials investigating uPAR-targeted FGS are ongoing in patients with oral cancer, lung cancer, and glioblastoma (EudraCT no. 2022-001361-12, 2021-004389-37 and 2020-003089-38). This evidence concerns the gene PLAUR and glioblastoma.